Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System DisordersGlobeNewsWire • 10/22/21
Palisade Bio Reports Second Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 08/24/21
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal SurgeryGlobeNewsWire • 07/29/21
Palisade Bio, University of California Team Up For Target Identification, Discovery, DevelopmentBenzinga • 07/13/21
Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical AdhesionsGlobeNewsWire • 06/15/21
Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative AdhesionsBenzinga • 05/13/21
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic SurgeryGlobeNewsWire • 05/13/21
Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in ChinaGlobeNewsWire • 05/07/21
Palisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI DysfunctionGlobeNewsWire • 05/04/21
